• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×

working
  • 01 Apr 2025

KNR: Solid Q4; Still Trading at a Discount to Net Cash


Kontrol Technologies Corp. (KNR:NEOL) | 0 0 0.0%


  • Atrium Research
    • Nicholas Cortellucci, CFA

    • 4 pages


 

What you need to know: • Kontrol Technologies reported Q4 financial results that were in line with our expectations. Revenue came in at $1.7M vs. our estimate of $1.8M and adjusted EBITDA was ($0.3M) vs. our estimate of ($0.2M). • KNR repurchased 1.8M shares in 2024 and 0.7M shares in 2025 thus far, decreasing its share count by 4% since Q4/23. • KNR ended the quarter with $12.6M in cash & equivalents with minimal debt ($0.22/share in net cash), placing it at a negative enterprise value. • Management continues to work on tuck-in acquisition opportunities to deploy its cash and grow the business. Yesterday after market close, Kontrol Technologies (KNR:Cboe, KNRLF:OTC) reported Q4 and 2024 financial results that were in line with our expectations. KNR ended the quarter with a cash and equivalents of $12.6M and negligible debt, compared to its market cap of $8.7M, demonstrating the deep value opportunity. We remain bullish on Kontrol as its business shifts to operating profitability in 2025 and it deploys capital on tuck-in acquisitions, all while operating in an industry with long-term secular growth. We are maintaining our BUY rating and $0.35/share target price on Kontrol Technologies. Key Highlights • Revenue in Q4 was $1.7M compared to our estimate of $1.8M and $1.7M in Q2, declining YoY due to the two disposed subsidiaries. 2024 revenue was $10.9M vs. our expectation of $11.0M. • Q4 gross margin of 51% compared to our expected 54% and 56% in Q4/23. Full year gross margin was 56% vs. 57% expected. • Adjusted EBITDA in Q4 of ($0.3M) compared to our estimate of ($0.2M). We were encouraged to see the consulting expenses drop to $0.1M from $0.6M in Q2 and $1.1M in Q3 due to the transaction related due diligence. 2024 adjusted EBITDA was ($0.5M) compared to our estimate of ($0.4M). • Net income of $0.1M in Q4 vs. our estimate of ($0.3M). 2024 net income was $12.2M compared to our estimate of $12.0M, including the $13.2M gain on the sale of assets from Q2. • KNR ended the quarter with $12.6M in cash and equivalents and $0.4M in debt. The $12.6M is made up of $2.1M cash, $7.0M in GICs/fixed income, and $3.6M in the iShares Bitcoin Trust ETF and related call options. • Management continues to expect a return to operating profitability in 2025 through cost reductions, streamlining of operations, organic growth, and operating leverage via tuck-in acquisitions.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

KNR: Solid Q4; Still Trading at a Discount to Net Cash


Kontrol Technologies Corp. (KNR:NEOL) | 0 0 0.0%


  • Published: 01 Apr 2025
  • Author: Nicholas Cortellucci, CFA
  • Pages: 4
  • Atrium Research


What you need to know: • Kontrol Technologies reported Q4 financial results that were in line with our expectations. Revenue came in at $1.7M vs. our estimate of $1.8M and adjusted EBITDA was ($0.3M) vs. our estimate of ($0.2M). • KNR repurchased 1.8M shares in 2024 and 0.7M shares in 2025 thus far, decreasing its share count by 4% since Q4/23. • KNR ended the quarter with $12.6M in cash & equivalents with minimal debt ($0.22/share in net cash), placing it at a negative enterprise value. • Management continues to work on tuck-in acquisition opportunities to deploy its cash and grow the business. Yesterday after market close, Kontrol Technologies (KNR:Cboe, KNRLF:OTC) reported Q4 and 2024 financial results that were in line with our expectations. KNR ended the quarter with a cash and equivalents of $12.6M and negligible debt, compared to its market cap of $8.7M, demonstrating the deep value opportunity. We remain bullish on Kontrol as its business shifts to operating profitability in 2025 and it deploys capital on tuck-in acquisitions, all while operating in an industry with long-term secular growth. We are maintaining our BUY rating and $0.35/share target price on Kontrol Technologies. Key Highlights • Revenue in Q4 was $1.7M compared to our estimate of $1.8M and $1.7M in Q2, declining YoY due to the two disposed subsidiaries. 2024 revenue was $10.9M vs. our expectation of $11.0M. • Q4 gross margin of 51% compared to our expected 54% and 56% in Q4/23. Full year gross margin was 56% vs. 57% expected. • Adjusted EBITDA in Q4 of ($0.3M) compared to our estimate of ($0.2M). We were encouraged to see the consulting expenses drop to $0.1M from $0.6M in Q2 and $1.1M in Q3 due to the transaction related due diligence. 2024 adjusted EBITDA was ($0.5M) compared to our estimate of ($0.4M). • Net income of $0.1M in Q4 vs. our estimate of ($0.3M). 2024 net income was $12.2M compared to our estimate of $12.0M, including the $13.2M gain on the sale of assets from Q2. • KNR ended the quarter with $12.6M in cash and equivalents and $0.4M in debt. The $12.6M is made up of $2.1M cash, $7.0M in GICs/fixed income, and $3.6M in the iShares Bitcoin Trust ETF and related call options. • Management continues to expect a return to operating profitability in 2025 through cost reductions, streamlining of operations, organic growth, and operating leverage via tuck-in acquisitions.

More Content

More Content

KNR: Light Q1 Financials; 15% Discount to Net Cash

Companies: Kontrol Technologies Corp.

Atrium Research

KNR: Trading at Cash with Proven Private Market Value

Companies: Kontrol Technologies Corp.

Atrium Research

Q1/25 Recap: All Our Research in One Place!

Companies: NIM SCZ DRX AUAU ARG OMG BQE DNG EDG KNR MOO NIM RIO SBIO LVG TOC TM SCZ CAPT GIGA APM FISH

Atrium Research

Q4/24 Recap: All Our Research in One Place!

Companies: NIM DRX AUAU OMG BQE DNG EDG KNR MOO NIM TOC TM CAPT FISH

Atrium Research

KNR: Still Finding its Footing After Dispositions

Companies: Kontrol Technologies Corp.

Atrium Research
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Acquisdata
      • Actinver
      • Actio Advisors
      • Asset TV
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD (hosted by Progressive)
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In